| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IRF8 |
| Uniprot No | Q02556 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-426aa |
| 氨基酸序列 | MCDRNGGRRLRQWLIEQIDSSMYPGLIWENEEKSMFRIPWKHAGKQDYNQEVDASIFKAWAVFKGKFKEGDKAEPATWKTRLRCALNKSPDFEEVTDRSQLDISEPYKVYRIVPEEEQKCKLGVATAGCVNEVTEMECGRSEIDELIKEPSVDDYMGMIKRSPSPPEACRSQLLPDWWAQQPSTGVPLVTGYTTYDAHHSAFSQMVISFYYGGKLVGQATTTCPEGCRLSLSQPGLPGTKLYGPEGLELVRFPPADAIPSERQRQVTRKLFGHLERGVLLHSSRQGVFVKRLCQGRVFCSGNAVVCKGRPNKLERDEVVQVFDTSQFFRELQQFYNSQGRLPDGRVVLCFGEEFPDMAPLRSKLILVQIEQLYVRQLAEEAGKSCGAGSVMQAPEEPPPDQVFRMFPDICASHQRSFFRENQQITV |
| 预测分子量 | 48,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IRF8重组蛋白的3篇参考文献示例(文献标题与作者为虚构示例，仅用于说明格式)：
1. **《重组IRF8蛋白的体外表达及功能验证》**
- 作者：Smith A, et al.
- 摘要：研究通过原核表达系统成功纯化重组IRF8蛋白，并验证其在调控巨噬细胞分化中的关键作用，揭示其与DNA结合的分子机制。
2. **《IRF8重组蛋白在自身免疫性疾病模型中的调控作用》**
- 作者：Zhang L, et al.
- 摘要：利用重组IRF8蛋白处理小鼠模型，发现其通过抑制TLR4信号通路减轻系统性红斑狼疮症状，提示潜在治疗应用价值。
3. **《IRF8与PU.1复合物的结构解析及功能研究》**
- 作者：Tanaka K, et al.
- 摘要：通过X射线晶体学解析重组IRF8与PU.1的复合物结构，阐明两者协同调控髓系细胞基因表达的分子基础。
(注：以上文献为示例，实际引用需检索PubMed等数据库获取真实研究。)
Interferon Regulatory Factor 8 (IRF8), also known as Interferon Consensus Sequence-Binding Protein (ICSBP), is a transcription factor belonging to the IRF family. It plays critical roles in immune cell development, particularly in myeloid cells (e.g., dendritic cells, macrophages) and B lymphocytes. Structurally, IRF8 contains a conserved N-terminal DNA-binding domain and a C-terminal interaction domain that facilitates dimerization with other transcription factors, such as PU.1. This cooperation is essential for regulating genes involved in immune responses, including cytokine signaling, antigen presentation, and pathogen defense.
IRF8 is pivotal in hematopoiesis, directing lineage commitment and suppressing excessive proliferation of myeloid progenitors. Dysregulation of IRF8 is linked to immune disorders and malignancies. For instance, IRF8 mutations or reduced expression are associated with chronic myeloid leukemia, autoimmune diseases, and immunodeficiency syndromes. Its tumor-suppressive role involves promoting differentiation and apoptosis while inhibiting oncogenic pathways.
Recombinant IRF8 protein is produced via heterologous expression systems (e.g., E. coli, mammalian cells) for functional studies. Researchers utilize it to investigate IRF8-DNA/protein interactions, signaling cascades, and its regulatory mechanisms in immune cells. Purified IRF8 is often tagged (e.g., His-tag) for ease of isolation and employed in assays like electrophoretic mobility shift assays (EMSAs), chromatin immunoprecipitation (ChIP), or cell-based experiments to modulate IRF8 activity. Its recombinant form also serves as a tool for developing therapeutic strategies targeting IRF8-related pathologies, including cancer immunotherapy and autoimmune disease interventions. Studies leveraging IRF8 recombinant protein continue to advance our understanding of immune regulation and precision medicine.
×
